|
Hemoglobin, g/dl
|
9.8 (8.16; 11.6)
|
11,4 (10,8; 13,0)
|
0,006
|
|
Anemia, n (%)
|
9 (81.8)
|
12 (46,2)
|
0,07*
|
|
WBC, *109/l
|
17.2 (12.8; 20.8)
|
9,85 (7,8; 13,8)
|
0,008
|
|
WBC in 1 week, *109/l
|
11.6 (8.2; 19.0)
|
7.6 (5.2; 11.9)
|
0.05
|
|
Granulocytes, cells in 1 μl
|
13728 (10112; 18654)
|
6445 (4914; 8787)
|
0,002
|
|
Granulocytes in 1 week, cells 1 μl
|
8944 (6560; 15390)
|
3314 (1840; 7240)
|
0,005
|
|
Granulocytes in 2 weeks, cells 1 μl
|
8925 (7700; 10332)
|
3408 (2907; 3975)
|
0.01
|
|
CRP, mg/l
|
100.0 (20.6; 120.0)
|
18.0 (10.3; 74.5)
|
0.01
|
|
ESR, mm/h
|
46.0 (42.0; 63.0)
|
25.5 (12.0; 50.0)
|
0.01
|
|
Ferritin, mg/ml
|
1287.0 (326.0; 3509.0)
|
128.0 (51.0; 224.0)
|
0.0006
|
|
LDH, U/l
|
714.0 (635.0; 796.0)
|
464.0 (423.0; 513.0)
|
0.006
|
|
Total protein, g/dl
|
6.7 (6.2; 7.0)
|
7.2 (6.8; 7.8)
|
0.004
|
|
Albumin, g/dl
|
2.1 (1.8; 2.5)
|
3.1 (2.9; 3.3)
|
0.0003
|
|
Hepatomegaly
|
10 (90.9)
|
10 (38.5)
|
0.003
|
|
Splenomegaly
|
6 (54.6)
|
5 (19.2)
|
0.05
|
|
Lymphadenopathy
|
5 (45.5)
|
8 (30.8)
|
0.47
|
|
Coagulopathy
|
4 (36.3)
|
0 (0.0)
|
0.005*
|
|
Interstitial lung disease
|
5 (45.5)
|
1 (3.9)
|
0.005*
|
|
Heart involvement
|
6 (54.6)
|
4 (15,4)
|
0.04*
|
|
CNS dysfunction
|
6 (54.6)
|
0 (0.0)
|
0.0001*
|
|
MAS before TCZ (any time point)
|
7 (63.6)
|
5 (19.2)
|
0.018*
|
|
MAS immediately precede TCZ
|
5 (45.5)***
|
0 (0.0)
|
0.001*
|
|
Outcomes during TCZ course
|
|
Corticosteroids discontinuation, n (%)
|
2/7 (28.6)
|
19/19 (100.0)
|
0.0001*
|
|
Corticosteroids discontinuation, days
|
167.0 (94.0; 237.0)
|
62.0 (34.0; 93.0)
|
0.005
|
|
Methotrexate discontinuation, due to remission of SoJIA, n (%)
|
1/8 (12.5)
|
8/24 (33.3)
|
0.39*
|
|
Cyclosporine A discontinuation, n (%)
|
3/7 (42.9)
|
8/13 (61.5)
|
0.64*
|
|
SoJIA relapses
|
5 (45.5)
|
2 (7.7)
|
0.016*
|
|
MAS during TCZ
|
5 (45.5)***
|
0 (0.0)
|
0.001*
|
|
Inactive disease
|
0 (0.0)
|
12/25** (48.0)
|
0.03*
|
|
TCZ-off remission
|
0 (0.0)
|
7/25** (28.0)
|
0.15*
|
